To obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of pancreatic cancer.
The study objectives are described below: 1. Obtain serum and plasma specimens longitudinally collected from approximately 140 subjects diagnosed with pancreatic cancer and are about to or are currently undergoing treatment and follow-up. Specimens will be used to evaluate CA 19-9 assays, currently under development, as an aid for monitoring recurrence or progressive disease. 2. To store any remaining specimens for use in future cancer research and to evaluate as yet undetermined biomarkers for the development of IVDs, including additional CA 19-9 assays, for monitoring the course of disease and therapy in subjects diagnosed with pancreatic cancer.
Study Type
OBSERVATIONAL
Enrollment
140
Physicians use the CA 19-9 test results to manage their patients
Boca Raton Regional Hospital
Boca Raton, Florida, United States
Broward Health Medical Center
Fort Lauderdale, Florida, United States
Harry & Jeanette Weinberg Cancer Institute
Baltimore, Maryland, United States
Kansas City VA Center
Kansas City, Missouri, United States
A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients with Pancreatic Cancer
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
New Hanover Regional Medical Center
Wilmington, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
GI Research Institute
Vancouver, British Columbia, Canada